The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.

[Photo by Wang Yiming/China.org.cn] Pfizer showcased new treatments for atopic dermatitis, the leading type of eczema, at the ...

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

ChatGPT recommendations regarding atopic dermatitis (AD) often differ from AAAAI/ACAAI practice parameter recommendations.

Medically reviewed by Katlein Franca, MD Eczema (atopic dermatitis) is a common skin condition that causes an itchy, inflamed ...

Prior treatment use did not affect the efficacy or safety of topical ruxolitinib cream 1.5% for up to 52 weeks among patients with atopic dermatitis.

If not controlled with the above measures, your eczema might require prescription treatments like corticosteroids or even ...

AI has shown promise by analysing data from patient records to recognise complex patterns within large datasets, which can aid in the ...